1. Home
  2. RCKT vs BEAM Comparison

RCKT vs BEAM Comparison

Compare RCKT & BEAM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCKT
  • BEAM
  • Stock Information
  • Founded
  • RCKT 1999
  • BEAM 2017
  • Country
  • RCKT United States
  • BEAM United States
  • Employees
  • RCKT N/A
  • BEAM N/A
  • Industry
  • RCKT Biotechnology: Pharmaceutical Preparations
  • BEAM Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • RCKT Health Care
  • BEAM Health Care
  • Exchange
  • RCKT Nasdaq
  • BEAM Nasdaq
  • Market Cap
  • RCKT 1.9B
  • BEAM 1.9B
  • IPO Year
  • RCKT N/A
  • BEAM 2020
  • Fundamental
  • Price
  • RCKT $16.98
  • BEAM $22.93
  • Analyst Decision
  • RCKT Strong Buy
  • BEAM Buy
  • Analyst Count
  • RCKT 9
  • BEAM 10
  • Target Price
  • RCKT $53.22
  • BEAM $47.00
  • AVG Volume (30 Days)
  • RCKT 641.8K
  • BEAM 998.5K
  • Earning Date
  • RCKT 11-12-2024
  • BEAM 11-05-2024
  • Dividend Yield
  • RCKT N/A
  • BEAM N/A
  • EPS Growth
  • RCKT N/A
  • BEAM N/A
  • EPS
  • RCKT N/A
  • BEAM N/A
  • Revenue
  • RCKT N/A
  • BEAM $352,567,000.00
  • Revenue This Year
  • RCKT N/A
  • BEAM N/A
  • Revenue Next Year
  • RCKT $382.35
  • BEAM $8.94
  • P/E Ratio
  • RCKT N/A
  • BEAM N/A
  • Revenue Growth
  • RCKT N/A
  • BEAM 339.83
  • 52 Week Low
  • RCKT $15.98
  • BEAM $18.85
  • 52 Week High
  • RCKT $32.53
  • BEAM $49.50
  • Technical
  • Relative Strength Index (RSI)
  • RCKT 44.74
  • BEAM 46.94
  • Support Level
  • RCKT $16.48
  • BEAM $21.79
  • Resistance Level
  • RCKT $17.75
  • BEAM $22.70
  • Average True Range (ATR)
  • RCKT 0.70
  • BEAM 1.09
  • MACD
  • RCKT 0.00
  • BEAM -0.07
  • Stochastic Oscillator
  • RCKT 20.75
  • BEAM 28.56

About RCKT Rocket Pharmaceuticals Inc.

Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis.

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.

Share on Social Networks: